Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Avrobio Inc (NQ: AVRO )

0.7910 +0.0200 (+2.59%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 20, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 202,610
Open 0.8048
Bid (Size) 0.7914 (24)
Ask (Size) 0.7975 (5)
Prev. Close 0.7710
Today's Range 0.7617 - 0.8460
52wk Range 0.7400 - 11.00
Shares Outstanding 43,696,470
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Avrobio's Pompe Disease Gene Therapy Shows Efficacy, Safety In Preclinical Study
 
Via Benzinga
AVROBIO Announces Preclinical Gene Therapy Data for Pompe Disease at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
From AVROBIO, Inc.
Via Business Wire

Performance

YTD
-80.42%
-80.42%
1 Month
-24.67%
-24.67%
3 Month
-46.19%
-46.19%
6 Month
-82.26%
-82.26%
1 Year
-91.30%
-91.30%

More News

Read More
AVROBIO Shares Jumps On Encouraging Data From Early-Stage Gene Therapy Study
Via Benzinga
AVROBIO Reports Positive Data From Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures
From AVROBIO, Inc.
Via Business Wire
Avrobio: Q1 Earnings Insights
Via Benzinga
Recap: Avrobio Q4 Earnings
Via Benzinga
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
Via Benzinga
AVROBIO to Present at the H.C. Wainwright Global Investment Conference
From AVROBIO, Inc.
Via Business Wire
AVROBIO Reports First Quarter 2022 Financial Results and Provides Business Update
From AVROBIO
Via Business Wire
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From AVROBIO, Inc.
Via Business Wire
AVROBIO to Present New Clinical and Preclinical Data at the ASGCT 25th Annual Meeting
From AVROBIO, Inc.
Via Business Wire
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From AVROBIO, Inc.
Via Business Wire
AVROBIO to Present at the 21st Annual Needham Virtual Healthcare Conference
From AVROBIO, Inc.
Via Business Wire
AVROBIO Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update
From AVROBIO, Inc.
Via Business Wire
After Fabry Trial Setback, Avrobio Hopes Rebound With Lysosomal Storage Disorder Data
Via Benzinga
The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
AVROBIO Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis
From AVROBIO, Inc.
Via Business Wire
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, & More
Via Talk Markets
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From AVROBIO, Inc.
Via Business Wire
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
Via Benzinga
AVROBIO Announces the Appointment of Sean O’Bryan as Chief Regulatory Officer
From AVROBIO, Inc.
Via Business Wire
AVROBIO to Present at Cowen’s 2nd Annual Genetic Medicines Summit
From AVROBIO, Inc.
Via Business Wire
AVROBIO to Present New Data from Phase 1/2 Clinical Trial in Cystinosis at WORLDSymposium™ 2022
From AVROBIO, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.